Rockefeller Capital Management’s Outlook Therapeutics OTLK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.59K Buy
8,000
+1,750
+28% +$1.67K ﹤0.01% 4404
2026
Q2
$9.9K Buy
+6,250
New +$3.88K ﹤0.01% 4022

Other funds holding OTLK

Rockefeller Capital Management's OTLK Position: Q3 2026 in Review

Rockefeller Capital Management increased its Outlook Therapeutics (OTLK) stake by 28% in Q3 2026, buying an estimated $1.67K and bringing the position to 8,000 shares worth $4.59K. The position accounts for ﹤0.01% of the portfolio, ranked #4404.

Rockefeller Capital Management first reported a position in OTLK in Q2 2026 and has held it in 2 quarters since. The position peaked at $9.9K in Q2 2026. 82 funds tracked by Wall St. Rank hold OTLK as of Q3 2026.

  • Rockefeller Capital Management held 8,000 shares of Outlook Therapeutics worth $4.59K as of Q3 2026.
  • Rockefeller Capital Management bought 1,750 Outlook Therapeutics shares in Q3 2026, an estimated $1.67K.
  • Outlook Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #4404 holding.
  • Rockefeller Capital Management first reported a position in Outlook Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Rockefeller Capital Management's Outlook Therapeutics position peaked at $9.9K in Q2 2026.
  • 82 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.